Halozyme, Acumen partner for ENHANZE drug delivery technology
Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.
Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.
US-based Noramco has acquired the Cambrex Drug Product Business Unit, which was formerly known as Halo Pharmaceuticals.
Integrated drug development solution company Altasciences has completed the expansion of its new laboratory facility in Columbia, Missouri in the US.
Basilea Pharmaceutica and iNtRON Biotechnology have signed an exclusive evaluation license and option agreement for the potential first-in-class clinical-stage antibacterial agent, tonabacase.
Canadian company PharmaDrug has signed a definitive agreement to acquire Securedose Synthetics, a privately-held pharmaceutical research and development company.
ThermoGenesis Holdings has opened a new 35,500ft² ReadyStart-IncuStart cGMP facility in Greater Sacramento in Northern California, US.
Caris Life Sciences and Moderna have signed a new multi-year agreement for advancing mRNA-based oncology therapeutics.
HBM Holdings wholly-owned subsidiary Nona Biosciences has signed an agreement for the expansion of its antibody discovery collaboration with BeiGene.
Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).
Salipro Biotech and Sumitomo Pharma have entered into a research partnership for advancing a drug discovery programme.